Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: A 5-year follow-up

Maturitas

Volumn 66, Issue 4, 2010, Pages 423-430

  Tuppurainen, Marjo ^a,b   Härmä, Kirsi ^c   Komulainen, Marja ^a   Kiviniemi, Vesa ^b   Kröger, Heikki ^a,b   Honkanen, Risto ^b   Alhava, Esko ^b   Jurvelin, Jukka ^a   Saarikoski, Seppo ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c SOUTH KARELIA CENTRAL HOSPITAL   (Finland)

Author keywords

BMD; Clodronate; HRT; Menopause; Osteoporosis

Indexed keywords

ALKALINE PHOSPHATASE; CLODRONIC ACID; ESTRADIOL PLUS NORETHISTERONE ACETATE; OSTEOCALCIN; PLACEBO; BONE DENSITY CONSERVATION AGENT; ESTRADIOL; ESTROGEN; NORETHISTERONE; NORETHISTERONE ACETATE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOATING; BONE DENSITY; BONE TURNOVER; BREAST CANCER; BREAST TENDERNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; ECZEMA; EPIGASTRIC PAIN; FEMALE; FINLAND; FLATULENCE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENORRHAGIA; NAUSEA; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; STROKE; ANALOGS AND DERIVATIVES; DRUG COMBINATION; DRUG EFFECTS; ESTROGEN THERAPY; FEMUR; LUMBAR VERTEBRA; METABOLISM; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATHOLOGY; POSTMENOPAUSE; PROSPECTIVE STUDY;

ALKALINE PHOSPHATASE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CLODRONIC ACID; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FEMUR; FINLAND; FOLLOW-UP STUDIES; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; NORETHINDRONE; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; PROSPECTIVE STUDIES;

EID: 77955717649     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2010.04.013     Document Type: Article

References (35)

1. M.H. Komulainen, H. Kröger, and M.T. Tuppurainen, et al. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial Maturitas 31 1998 45 54
2. J.A. Cauley, J. Robbins, and Z. Chen, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial JAMA 290 2003 1729 1738
3. E. Banks, V. Beral, and G. Reeves, et al. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women JAMA 291 2004 2212 2220
4. J.A. Kanis, N. Burlet, and C. Cooper, et al. (ESCEO) European guidance for the diagnosis and management of osteoporosis in postmenopausal women Osteoporos Int 19 2008 399 428
5. D.J. Torgerson, and S.E. Bell-Syer Hormone replacement therapy and prevention of non-vertebral fractures: a meta-analysis of randomized trials JAMA 285 2001 2891 2897
6. E. Sornay-Rendu, P. Garnero, and F. Munoz, et al. Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study Bone 33 2003 159 166
7. Y.Z. Bagger, L.B. Tankó, and P. Alexandersen, et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study Bone 34 2004 728 735
8. N.B. Watts, and D.L. Diab Long-term use of bisphosphosphonates in osteoporosis J Clin Endocrinol Metab 95 4 2010 1555 1565
9. M.E. Fadanelli, and H.G. Bone Combining bisphosphonates with hormone therapy for postmenopausal osteoporosis Treat Endocrinol 3 2004 361 369
10. S. Eviö, A. Tiitinen, and K. Laitinen, et al. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis J Clin Endocrinol Metab 89 2004 626 631
11. E. McCloskey, P. Selby, and M. Davies, et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study J Bone Miner Res 19 2004 728 736
12. E.V. McCloskey, M. Beneton, and D. Charlesworth, et al. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind. Placebo-controlled randomized study J Bone Miner Res 21 2007 135 141
13. M. Tuppurainen, R. Honkanen, and H. Kroger, et al. Osteoporosis risk factors, gynaecological history and fractures in perimenopausal women-the results of the baseline postal enquiry of the Kuopio Osteoporosis Risk Factor and Prevention Study Maturitas 17 1993 89 100
14. J. Saarelainen, R. Honkanen, and E. Vanninen, et al. Cross-calibration of Lunar DPX-IQ and DPX dual-energy X-ray densitometers for bone mineral measurements in women: effect of body anthropometry J Clin Densitom 8 2005 320 329
15. M.T. Parviainen, I. Kuronen, and H. Kokko, et al. Two-site enzyme immunoassay for measuring intact human osteocalcin in serum J Bone Miner Res 9 1994 347 354
16. R. Lindsay, F. Cosman, and R.A. Lobo, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial J Clin Endocrinol Metab 84 9 1999 3076 3081
17. H.G. Bone, S.L. Greenspan, and C. McKeever, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density J Clin Endocrinol Metab 85 2000 720 726
18. M.B. Tiras, V. Noyan, and A. Yildiz, et al. Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study Hum Reprod 15 10 2000 2087 2092
19. S. Palomba, F. Orio Jr., and A. Colao, et al. Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis J Clin Endocrinol Metab 87 4 2002 1502 1508
20. S.L. Greenspan, N.M. Resnick, and R.A. Parker Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial JAMA 289 2003 2525 2533
21. L. Tseng, W. Sheu, and E. Ho, et al. Effects of alendronate combined with hormone replacement therapy on osteoporotic postmenopausal Chinese women Metab Clin Exp 55 2006 741 747
22. P.B. Rapuri, J.C. Gallagher, and G. Haynatzki Endogenous levels of serum estradiol and sex hormone binding globulin determine bone mineral density, bone remodeling, the rate of bone loss, and response to treatment with estrogen in elderly women J Clin Endocrinol Metab 89 10 2004 4954 4962
23. B. Tang, G.D. Eslick, and C. Nowson, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in older people: a meta-analysis Lancet 370 2007 657 666 24
24. J.C. Frith, J. Mönkkönen, and S. Auriola, et al. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis Arthritis Rheum 44 9 2001 2201 2210
25. N. Kohno Treatment of breast cancer with bone metastasis: bisphosphonate treatment - current and future Int J Clin Oncol 13 2008 18 23
26. E. McCloskey, A. Paterson, and J. Kanis, et al. Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer Eur J Cancer 46 3 2010 Feb 558 565
27. P. Szulc, and P.D. Delmas Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis Osteoporos Int 19 2008 1683 1704
28. J.J. Caro, K.J. Ishak, and K.F. Huybrechts, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice Osteoporos Int 15 2004 1003 1008
29. V. Rabenda, R. Mertens, and V. Fabri, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women Osteoporos Int 19 2008 811 818
30. G.L. Anderson, M. Limacher, and A.R. Assaf, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 291 2004 1701 1712
31. G. Wells, P. Tugwell, and B. Shea, et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women Endocr Rev 23 2002 529 539
32. H.E. Meyer, C.M. Lofthus, and A.J. Sogaard, et al. Change in the use of hormone replacement therapy and the incidence of fracture in Oslo Osteoporos Int 20 5 2009 827 830
33. M. Canonico, G. Plu-Bureau, G.D. Lowe, and P.Y. Scarabin Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis BMJ 31 336(7655) 2008 1227 1231
34. C. Dane, and B. Dane Cetin A comparision of the effects of raloxifene and low-dose hormone replacement therapy on bone turnover in the treatment of postmenopausal osteoporosis Gyn Endocrinol 23 2007 398 403
35. M. Cambaggiani, B. Cappagli, and M. Ciaponi, et al. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women Maturitas 59 2008 2 6